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Abstract
Background: Health Canada has defined rare diseases as life-threatening, seriously debilitating, or serious chronic
conditions affecting a very small number of patients (~1 in 2,000 persons). An estimated 9 % of Canadians suffer
from a rare disease. Drugs treating rare diseases (DRDs) are also known as orphan drugs. While Canada is currently
developing an orphan drug framework, in the United States (US), the Orphan Drug Act (ODA) of 1983 established
incentives for the development of orphan drugs.
This study measured total annual expenditure of orphan drugs in Canada (2007–13) and estimated future (2014–18)
orphan drug expenditure.
Methods: Orphan drugs approved by the US Food and Drug Administration (FDA) in the US were used as a proxy
for the orphan drug landscape in Canada. Branded, orphan drugs approved by the FDA between 1983 through
2013 were identified (N = 356 unique products). Only US orphan drugs with the same orphan indication(s)
approved in Canada were included in the analysis. Adjustment via an indication factoring was applied to products
with both orphan and non-orphan indications using available data sources to isolate orphan-indication sales. The
IMS Health MIDAS database of audited biopharmaceutical sales was utilized to measure total orphan drug
expenditure, calculated annually from 2007–2013 and evaluated as a proportion of total annual pharmaceutical
drug expenditure (adjusted to 2014 CAD).
Results: Between 2007 and 2013, expenditure was measured for a final N = 147 orphan drugs. Orphan drug
expenditure totaled $610.2 million (M) in 2007 and $1,100.0 M in 2013, representing 3.3– 5.6 % of total Canadian
pharmaceutical drug expenditure in 2007–2013, respectively. Future trend analysis suggests orphan drug
expenditure will remain under 6 % of total expenditure in 2014–18.
Conclusions: While the number of available orphan drugs and associated expenditure increased over time, access
remains an issue, and from the perspectives of society and equity, overall spending on orphan drugs is lower
relative to the number of patients affected with an orphan disease in Canada. The overall budget impact of orphan
drugs is small and fairly stable relative to total pharmaceutical expenditure. Concerns that growth in orphan drug
expenditure may lead to unsustainable drug expenditure do not appear to be justified.
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Background
Health Canada has defined a rare disease as a life-
threatening, seriously debilitating, or serious and chronic
condition affecting a relatively small number of patients: 1
in 2,000 persons [1]. It is estimated that 1 in 12 Canadians,
approximately 3 million people or 9 % of the Canadian
population, suffer from a rare disease [2]. Drugs that have
been developed to treat rare diseases, also known as drugs
treating rare diseases (DRDs), are designated as orphan
drugs if certain criteria are met, such as criteria regarding
prevalence or severity of the condition, as well as the lack
of existing treatments or significant improvement com-
pared to the standard drug treatment [1].
Almost all developed countries have a regulatory frame-
work for orphan drugs, i.e., legislative policy or regulations
that set the criteria and requirements for orphan drug
designation, market authorization, post-marketing moni-
toring and financial incentives, etc. [3]. Orphan drug
policies in these countries have dramatically increased the
approval of orphan drugs. The United States (US) was the
first nation to introduce orphan drug legislation with the
Orphan Drug Act (ODA) of 1983 [4].
In the US, the ODA has been successful in incentivizing
manufacturers to research and commercialize orphan drugs
for the treatment of a variety of previously underserved
conditions including acute myeloid leukemia, chronic
lymphocytic leukemia, multiple myeloma, myelodysplastic
syndromes, Gaucher disease and Hunter syndrome. Prior
to passing of the ODA in 1983, fewer than 10 drugs
for orphan conditions were available to patients in
the US. In 2013, the Federal Drug and Administration
(FDA) website listed more than 400 orphan drugs
that have received marketing approval (including both
new molecular entities and supplemental applications/
indications) [5]. The ODA has served as a model for
legislation, and following 1983, a number of other
countries subsequently introduced orphan drug pol-
icies, including Japan (1993), Australia (1998) and the
EU (2000) [6, 7].
Canada is one of the few developed nations without a
regulatory framework for orphan drugs and there is
currently no official “orphan disease” status in Canada
[3]. As a result, patient access has been negatively im-
pacted. Approximately half of approved orphan drugs in
the US are available in Canada, with additional variation
in access by province [2, 3]. However, Canada has recog-
nized the importance of orphan drug legislation and in
October 2012, Health Canada announced the development
of a new framework for the designation, authorization and
monitoring of orphan drugs in order to benefit Canadians
with rare diseases and spur research and innovation in
Canada [8].
While orphan drugs have the potential to offer great
clinical value and substantial benefits to the patient and
to society, payer sensitivity to orphan drugs is increasing.
Payers perceive high therapy costs and perceptions of
disproportionate use of resources for small patient popu-
lations coupled with healthcare budget constraints [9].
However, little evidence or data has been publically
generated with regard to actual orphan drug expenditure
in Canada. Real-world data is necessary to inform payer
and policy discussions on access and reimbursement, as
well as to aid in understanding the value of investment
in orphan drugs.
This study had several objectives. The first objective
was to estimate the financial impact of orphan drugs on
the total pharmaceutical expenditure from 2007 to 2013
in Canada. The second objective was to extrapolate




Canada does not currently have an official process for
orphan drug designation and thus does not have an
official list of drugs with orphan drug designation.
Therefore, this analysis used the orphan drugs that have
received marketing approval by the FDA in the US as a
proxy list of all orphan drugs, and included only those
drugs with the orphan indication(s) also approved in
Canada. The Health Canada website was used to deter-
mine drug approvals and approved indications in
Canada. The IMS Health MIDAS database was used to
measure orphan drug and total drug expenditure in
Canada between 2007 and 2013.
Data sources
Food and Drug Administration (FDA) website
A list of all orphan drugs that have been approved in the
US since the passage of the Orphan Drug Act in 1983
up to the end of 2013 was identified from the US
FDA Orphan Drug Designations and Approvals Website
(N = 365 unique products) [5].
Only branded products approved for an orphan indica-
tion were included in the analysis (N = 356 unique brand
name products out of the total 365 brand and generic
products). This analysis focused on orphan drug expend-
iture between 2007 and 2013; however, all drugs ap-
proved up to the end of 2013 were considered in order
to evaluate all orphan drugs that had received approval
prior to 2007, and which continue to factor in orphan
drug expenditure during the study analysis period.
Health Canada website
The Health Canada website was used to determine and
include only those US orphan drug products which
received approval in Canada [10]. Because approved
indications in the US may differ from those approved in
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Canada, we additionally evaluated approved indications
in Canada, and only considered those products for
which the orphan indication or at least one orphan indi-
cation (in the case of multiple orphan indications) was
also approved in Canada.
IMS Health MIDAS database
The IMS Health MIDAS database was utilized to iden-
tify sales for the identified branded, orphan drugs [11].
MIDAS integrates and extends IMS National Audits, the
IMS ‘building blocks’ which accurately detail estimated
product volumes, trends and market share by product
and therapy class, through retail and non-retail channels.
Sales data are collected at the unit level of the pack and
identifiable information for each pack includes product
name, manufacturer name, dose form (e.g., tablets), dose
strength (e.g., 50 mg), and number of doses (e.g., 20
tablets). In Canada, MIDAS tracks the direct sales (i.e.,
sales invoices) of pharmaceuticals from the manufac-
turer to pharmacies or hospitals. MIDAS also tracks
indirect sales (sales going through a middleman i.e., the
wholesaler) to pharmacies and hospitals. MIDAS tracks
inflow or what these different channels are purchasing
(i.e., the sales made into those outlets). MIDAS repre-
sents the full Canadian market through representative
panel projections for both retail and hospital channels.
The data are routinely used by governments and aca-
demics in Canada to best understand market volumes
and growth.
Partial orphans
Since a drug may be approved for multiple indications,
further evaluation was undertaken for “partial orphans”,
or those products with both orphan and non-orphan
indications. Of the 356 branded orphan drugs designated
by the FDA, 65 (18 %) were identified as partial orphans
in the US.
MIDAS sales data does not comprehensively segment
by indication. In a parallel analysis of orphan drug
expenditure in the US, in-depth analysis was conducted
for the partial orphan drugs in order to determine an
indication factor to apply to the sales for each partial
orphan product to isolate and include only orphan indi-
cation(s) sales. Since sources for indication factors were
limited in Canada (limited data sources or financial
reporting; smaller population size, particularly for or-
phan diseases, etc.), indication factors identified for the
US analysis were used in Canada as a proxy. Approval
dates for orphan and non-orphan indications in Canada
were also considered as applicable.
In the US analysis to determine an indication factor
for each partial orphan, to estimate the proportion of
total drug sales spent on the orphan indication(s),
several US sources were consulted including the Cowen
and Company Equity Research Health Care Therapeutic
Categories Report published March 2014 and manufac-
turers’ audited financial reports [12]. The Cowen Report
included relevant information for some orphan drugs
such as estimates of therapy area sales by product (e.g.,
US Rheumatoid Arthritis Market Model) or product
sales by indication (e.g., Abraxane Pancreatic Cancer
Revenue Model). Additionally, an analysis of US phys-
ician office claims data was conducted in order to assess
diagnoses associated with prescriptions among a large
sample of US physicians, to quantify the number of
orphan diagnoses associated with prescriptions of a
partial orphan drug. Similarly, another source available
was the diagnosis value in MIDAS. The diagnosis value
is derived from a survey that is administered to office-
based physicians and is a measure of physician-reported
indications for prescribed drugs. Specifically, it calculates
the proportion of prescriptions for a product form
strength that is prescribed for a diagnosis. It is applicable
to drugs prescribed from office-based physicians but
limited for any hospital-based drugs. Lastly, reported
epidemiology (incidence or prevalence rates) in the US
was used to determine the different disease population
proportions. All available sources were evaluated with
the indication factor from the most robust source (tak-
ing into account sample size [number of claims], setting
of care, etc.) being applied to the total product sales in
order to measure sales associated with orphan indica-
tions. Approval dates were also considered as applicable.
Measurements
Total orphan drug expenditure was calculated annually
from 2007–2013 and further reported as a proportion of
total annual pharmaceutical drug expenditure, also derived
from MIDAS. Expenditure was recorded in Canadian dol-
lars (CAD) at the time of the sale. All expenditure was
adjusted to 2014 CAD using the Canadian Consumer Price
Index [13]. Trends in total orphan drug expenditure were
assessed over time. In an exploratory analysis, major
therapeutic categories of orphan indications were exam-
ined and expenditure for orphan drugs with oncology
indications was evaluated, and reported, as a subset of all
orphan drugs.
Future trend analysis
A future trend analysis was evaluated to estimate orphan
drug sales from 2014–2018. Orphan drug sales from
2007–2013 were used to project 2014–2018 sales.
Because we observed a gradual increase in orphan drug
spending over time from 2007–13 (i.e., a generally
consistent linear trend), suggesting that the orphan drug
segment has historically been relatively stable, we used a
linear trend model. While various factors impact future
orphan drug spending, we believe this was an appropriate
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option given the lack of data needed for a more complex
analysis (e.g., no official orphan drug approval rate in
Canada). Future estimated orphan drug expenditure was
evaluated as a proportion of projected future total drug
expenditure in Canada based on the IMS Health Market
Prognosis forecasts [14]. IMS Market Prognosis is a
strategic market forecasting publication that combines
historical data and macroeconomic indicators with the
identification and evaluation of key future issues to feed
into an econometric model. IMS Market Prognosis pro-
vides a 5-year forecast of total market sales based on
rigorous evaluation of the key events affecting the market-
place (e.g., legislative changes, improved market ac-
cess for orphan drugs, major new product launches,
cost-containment measures, generic competition, etc.).
Market Prognosis provides a global pharmaceutical out-
look with 49 in-depth country forecasts. Because the
Market Prognosis forecast for total pharmaceutical spend
includes three categories: Brand name prescriptions, Gen-
eric prescriptions, and Other (over-the-counter [OTC],
non-categorized Rx and other Rx; which accounted for
14 % of the total pharmaceutical spend in 2013), the an-
nual growth rate for brand and generic prescriptions from
the forecast was applied to the 2013 MIDAS data for total
pharmaceutical expenditure, to calculate adjusted total
pharmaceutical expenditure for prescription pharmaceuti-
cals only for each year from 2014–2018.
Results
Of the 356 branded products identified from the FDA
website, MIDAS captured sales for 147 unique orphan
drugs in Canada between 2007 and 2013, of which, 39
(26.5 %) were partial orphan drugs. Reasons for sales
data not being available include the drug not having
been approved in Canada, the orphan indication in the
US not being approved in Canada, funding for the drug
being unavailable in Canada, the product no longer
being marketed in Canada or other reasons, such as
MIDAS coverage limitations (i.e., infrequent cases where
sales are not audited). In our review of the Health
Canada website to identify “matches” for US orphan
drugs, we found a match to a product in Canada (i.e., a
Notice of Compliance [NOC]) for 207 orphan drugs. Of
these 207 orphan drugs, 11 orphan drugs did not have
the orphan indication approved in Canada, and were not
included in the final sample for analysis. We do not
know the reasons for the MIDAS data not including 49
other orphan products with a NOC in Canada. It is
possible that these drugs have been discontinued or have
not actually been marketed in Canada.
Following indication factoring and adjustment for
partial orphan drugs, total orphan drug expenditure to-
taled $610.2 million (M) in 2007 and $1,100.0 M in 2013,
representing 3.3– 5.6 % of total Canadian pharmaceutical
drug expenditure in 2007 and 2013, respectively (Table 1;
Fig. 1). Orphan only drugs represented 2.9– 4.4 % of total
Canadian drug sales from 2007–2013. Partial orphan
drugs represented 0.4–1.2 % of total Canadian drug sales
from 2007–2013.
While orphan drug expenditure increased over time, it
is important to note that the number of orphan drugs
approved and reimbursed in Canada has also increased
over time, with MIDAS capturing sales for a total of 95
unique orphan drugs in 2007, which increased to 133
orphan drugs in 2013.
Major therapeutic categories of indications were evalu-
ated and oncology was the most common therapeutic
class, with 57 (38.8 %) out of 147 orphan drugs identi-
fied with an orphan oncology indication. Expenditure for
these oncology-related orphan drugs totaled $227.8 M in
2007 and $474.7 M in 2013, representing 37.3 and
43.2 % of total orphan drug expenditure, respectively.
In the future trend analysis, a linear trend line was cre-
ated using 2007–2013 sales (in millions), with equation
y = 80.253x + 509.16, and with R2 = 0.9871, resulting in
sales for 2014 to 2018 of $1,151.2 M to $1,472.2 M,
respectively, representing a 27.9 % increase between
2014 and 2018 (Fig. 2). IMS Health Market Prognosis
Table 1 2007–2013 Canadian Orphan Drug Landscape and Expenditure (2014 CAD, Millions)
Measure 2007 2008 2009 2010 2011 2012 2013
# “Orphan only” drugs captured N = 108 70 74 73 79 81 91 99
# “Partial Orphan” drugs captured N = 39 25 26 27 28 30 31 34
# Total Orphan drugs captured N = 147 95 100 100 107 111 122 133
“Orphan Only” Drug Expenditure ($M) 537.6 586.7 649.2 692.6 729.3 786.8 868.0
“Partial Orphan” Drug Expenditure ($M) 72.6 82.5 94.5 125.5 151.2 202.8 232.0
Total Orphan Drug Expenditure ($M) 610.2 669.2 743.7 818.1 880.5 989.6 1,100.0
% “Orphan Only”/Total Orphan Expenditure 88.1 % 87.7 % 87.3 % 84.7 % 82.8 % 79.5 % 78.9 %
% “Partial Orphan”/Total Orphan Expenditure 11.9 % 12.3 % 12.7 % 15.3 % 17.2 % 20.5 % 21.1 %
Total Pharmaceutical Expenditure ($M) 18,233.6 19,598.1 20,514.4 20,628.6 19,976.3 19,746.0 19,665.7
% Total Orphan/Total Pharmaceutical Expenditure 3.3 % 3.4 % 3.6 % 4.0 % 4.4 % 5.0 % 5.6 %
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forecasts were adjusted to reflect prescription pharmaceu-
ticals only, and 2014–2018 Canadian total drug sales were
estimated at $20,413 M to $25,255 M, representing a
23.7 % increase from 2014 to 2018. Thus, the projected
orphan drug sales represent 5.6 to 5.8 % of total Canadian
drug expenditure from 2014 to 2018, respectively (Fig. 3).
Discussion
The ODA led to an increase in the number of approved
orphan drugs in the US, which also led to an associated
increase in the number of drugs available to benefit
many people with previously underserved rare condi-
tions in Canada. While associated orphan drug expend-
iture has increased, the population using these orphan
drugs is relatively small. Total orphan drug expenditure,
when considered out of total drug expenditure, is
comparatively low, representing less than 6 % of total
pharmaceutical expenditure. While both total orphan
drug and total drug expenditure are forecasted to
increase, future trend analysis suggests that orphan drug
expenditure in 2014–18 will remain stable below 6 % as
a proportion of total drug expenditure. This may be
related to drug spending accounting for a declining
share of total health dollars, as reported by the Canadian
Institute for Health Information in 2013 [15]. To aid in
the interpretation of our study findings, in a broader
context, drug expenditure represents a minority share
when considered out of total health care expenditure.
For example, in 2013, total spending on drugs (including
non-prescription drugs [e.g., OTC]) was estimated to
represent only 16 % of the total $211 billion spent
on health care in Canada, and drug spending growth
(2.4 %) was slower compared to both hospital
spending (2.6 %) and physician spending (3.6 %
growth) [15].
Orphan drug policies in other countries, such as the
ODA in the US, were created to address the unmet need
for developing therapies to treat rare diseases. Canada is
now following these trends, and is currently developing
orphan drug policies. Orphan drug policies have led to
an increase in the number of drugs to treat patients with
rare or orphan diseases in those countries, as well as in
Canada. In our analysis, MIDAS captured 95 orphan
drugs in 2007 which increased to 133 orphan drugs in
2013. However, we found a significant disparity in the
availability of orphan drugs in Canada when we com-
pared the number of unique orphan drugs identified in
Canada to the number identified in the US during the
same time period. In our parallel US analysis, we
captured sales in MIDAS for a total of 316 unique
orphan drugs between 2007 and 2013 (out of the total
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Fig. 1 2007–2013 Orphan Drug Expenditure out of Total Canadian Drug Expenditure
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total of 147 unique orphan drugs were captured in
Canada in MIDAS during the same time period
demonstrating the disparity in access, consistent
with other reports that more than half of the or-
phan drugs approved in the US are not available in
Canada [2, 3].
In our analysis, a quarter of available orphan drugs (39/
147) were also indicated to treat non-orphan conditions.
This is often not mentioned in critiques of the costs of
orphan drugs, and our indication factoring analysis sug-
gests that the majority of unadjusted “partial orphan” drug
sales are for non-orphan indications. Adjusted “partial
Fig. 2 Current (2007–2013) and Future (2014–2018) Orphan Drug Spending
Fig. 3 Current (2007–2013) and Future (2014–2018) Total Drug Spending
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orphan” drug expenditure represented only 5.6– 9.1 %
of unadjusted “partial orphan” drug expenditure from
2007–2013.
While our analysis focused on orphan drug expend-
iture, it is important to consider that these orphan drugs
benefit many people with previously underserved rare
conditions. Furthermore, these drugs offer significant
value to both patients and society such as improvements
in health, survival and quality of life, reductions in costly
hospitalizations, reduced disabilities, and increased ability
to go back to work, resulting in increased productivity.
The findings from this analysis suggest that investment in
drugs for orphan diseases appears to be justified in
Canada. According to the Canadian Organization for Rare
Disorders, an estimated 9 % of Canadians suffer from a
rare disease. This has been termed as a “paradox of rarity”,
in which an individual disease may be rare, but a signifi-
cant proportion of a country’s population may be affected
by a rare disease [16]. Interestingly, expenditure on or-
phan drugs represented less than 6 % of total pharma-
ceutical expenditure in Canada from 2007–2013.
Although spending on an individual patient level may
seem disproportionate compared to drug spending on
the individual basis for non-orphan drugs, from the
perspectives of society and equity, overall spending on
orphan drugs is low, considering the number of pa-
tients affected with an orphan disease in Canada, and
access remains an issue.
We did not identify any other published studies that
evaluated the costs of orphan drugs in Canada. However,
our parallel analysis in the US found orphan drug
expenditure was generally higher in the US than in
Canada (4.8– 8.9 % of total US drug expenditure be-
tween 2007 and 2013), while both future trend analyses
similarly suggested slowing down in the growth of or-
phan drug expenditure. Furthermore, a few recent stud-
ies have examined the budget impact of orphan drugs in
Europe [17–20]. Although methods and data sources
varied (based on sales data, disease-based epidemio-
logical models, etc.) limiting comparisons, findings sug-
gest that orphan drug expenditure as a percentage of
total pharmaceutical sales in Europe and Canada is
comparable. Estimates ranged from 2.5 % in Sweden
and 3.1 % in France in 2012 [17], 1.6– 4.2 % from
2007–2012 in the Netherlands [18], 1.9– 4 % from
2008–2013 in Belgium [19] and 3.3 % in 2010 in
Europe (Eurozone + UK) [20], with growth expected
to slow or peak and level off. Comparisons are fur-
ther limited due to varying country-specific access
and reimbursement guidelines and policies.
Limitations
There are a number of limitations with this analysis.
MIDAS database coverage is limited in some cases, for a
few individual specialty products which may have unique
distribution arrangements which prevent IMS from
auditing their sales. However, this is infrequent and this
does not impact the audit at the national level for the
majority of products. This limitation could result in an
underestimation of orphan drug sales. Furthermore, IMS
applies custom methodologies as needed to ensure pro-
jections are as valid as possible. Additionally, the future
trend analysis does not account for changing trends
following final approval and implementation of the
orphan drug framework in Canada, which could result
in an underestimation of forecasted orphan drug spend-
ing. While various factors impact future orphan drug
spending, we chose a linear trend model for the future
analysis, given the lack of data needed for a more
complex analysis. The future trend analysis relied on
historical expenditure and historical trends and does not
account for any potential heightened focus of the
pharmaceutical industry on R&D for orphan drugs.
However, our R2 was quite high, and suggests our model
may be a good fit and may explain much of the variance.
Our analysis also does not focus on any specific high-
cost “blockbuster” orphan drugs and instead considered
overall orphan drug costs. As Canada is currently devel-
oping an orphan drug framework, orphan drugs ap-
proved by the FDA in the US were used as a proxy for
the orphan drug landscape in Canada. Differences in
indication approvals may vary between the US and
Canada. While indication differences were reviewed to
ensure US orphan indication(s) were also approved in
Canada, it is a limitation that any additional indications
approved in Canada, but not approved in the US were
unaccounted for. Additionally, there is the potential for
off-label use of orphan drugs as the sales data do not
have indications associated with sales. Not thoroughly
excluding non-orphan drug sales may result in an over-
estimation of total orphan drug sales. However, prior
authorization or special authorization is often used by
payers as a condition for reimbursement which mini-
mizes the potential for off-label use, especially for high
cost drugs. Finally, our analysis focused on brand orphan
drugs only, including those approved pre-2007. It is pos-
sible that any generics of orphan drugs that have become
available have eroded brand market share and also con-
tribute to the orphan drug budget, although at a steep
discount; on average, costs of generics are from 80–
85 % lower than brand products [21]. Thus, this may re-
sult in a slight underestimation.
Conclusions
The analysis shows that total spending on orphan
drugs represents a small share of overall pharma-
ceutical spending and the overall budget impact of
orphan drugs has remained fairly stable relative to
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total pharmaceutical expenditure. Future orphan drug
spending is estimated to remain low in relation to overall
pharmaceutical spending. Concerns that growth in orphan
drug expenditure may lead to unsustainable drug expend-
iture do not appear to be justified.
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